ARCHIVES

NKTR-102 Shows 29 Percent Response in Phase II Study

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Overdiagnosis Can Result In Harm To Patients, Experts Say.

November 3, 2006

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

In Brief: Hammer Appointed To New Three Year Term, Says As Panel Chairman; ACCC Elects Yarbro, Moorhead

March 16, 1984

Blackburn Wins BMS Award

May 23, 2003

NCI Health Disparities Center Will Attempt To Influence Policy, Harold Freeman Says.

November 3, 2000

2015: “A Challenge For Our Generation,” AACR Says

July 18, 2003